The Lancet has overtaken the New England Journal of Medicine as the medical journal with the highest impact factor, according to Clarivate’s 2022 update to its Journal Citation Reports. And the jump wasn’t subtle: The Lancet’s impact factor – a controversial measure of how often a journal’s papers are cited on average – more than doubled from last year.
Lancet can thank the COVID-19 pandemic for its surge.
In separate news, Clarivate suppressed three journals for self-citation, and warned a half dozen others.
As we’ve written in posts on previous years’ reports:
A postdoc at New York University’s Grossman School of Medicine who the U.S. Office of Research Integrity found engaged in research misconduct while a postdoc at another institution has been awarded an NIH grant just months after being sanctioned.
The postdoc, Shuo Chen, didn’t admit or deny the ORI’s findings, but agreed to one year of supervision for any research funded by the U.S. Public Health Service, which includes the NIH, as we’ve previously reported.
That year began on Feb. 28, 2022, and less than four months later Chen was awarded a coveted and competitive K99 “pathway to independence” grant for “Elucidating circuit mechanisms of brain rhythms in the aging brain” on June 15, according to NIH RePORTER. The $135,945 grant is from the National Institute on Aging.
Chen is listed as a postdoc on the lab website of NYU School of Medicine neuroscientist Zhe Sage Chen (no relation), and also appears in a 2021 photo of members of György Buzsáki’s NYU lab. The grant abstract mentions training in the labs of Zhe Sage Chen, Buzsáki, and Thomas Wisniewski, director of NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment and its Alzheimer’s Disease Research Center.
We emailed Shuo Chen for comment but have not heard back. NYU Langone Health media relations sent us this statement after we reached out to Zhe Sage Chen for comment:
An Elsevier journal has sat for two years on its decision to retract 10 papers by researchers with known misconduct issues, according to emails seen by Retraction Watch.
The Journal of the Neurological Sciences had decided by June 2020 to retract the articles by Yoshihiro Sato and Jun Iwamoto, who are currently in positions four and six on our leaderboard of retractions, according to the emails. But the papers still haven’t been retracted, to the disappointment of one of the data sleuths who raised concerns about the work – and in the meantime have been cited more than a dozen times, according to Clarivate’s Web of Science.
As Andrew Grey, of the University of Auckland, in New Zealand, wrote to a staffer at the Committee on Publication Ethics (COPE) who became involved in the case:
A pharmacology researcher with four retractions appears to have left the University of Pennsylvania, where he had worked for at least 30 years and won more than $7 million in NIH grants.
The school’s faculty page for William Armstead, who held a research professorship in Anesthesiology and Critical Care, now bears only the statement that “Dr. Armstead may no longer be affiliated with the Perelman School of Medicine.” Penn Medicine has not responded to our request for comment.
In May, we reported that Armstead was up to four retractions after the Journal of Neurotrauma had retracted three articles at the researcher’s request.
Elsevier plans to remove the introduction from a book on mineralogy after investigating allegations of plagiarism, including from another Elsevier publication, according to emails obtained by Retraction Watch.
Photo Atlas of Mineral Pseudomorphism by J. Theo Kloprogge and Robert Lavinsky, was published in 2017 and still appears to be for sale for $100 for a hardcover and ebook bundle. (The usual price is $200, but there is a sale on at the time of this writing.) Its listing on ScienceDirect includes the introduction with no note about removal.
As we’ve previously reported, Elsevier last year retracted an entire book by Kloprogge, an adjunct professor at the University of the Philippines Visayas and honorary senior fellow at the University of Queensland, that plagiarized heavily from Wikipedia.
According to the emails we obtained, Gloria Staebler, of mineralogical publisher Lithographie, Ltd., noticed the plagiarism in the book in May while preparing to formally publish a manuscript by Si and Ann Frazier that had been circulated in a mineral club newsletter in 2005. In a May 31st email to an editor at Elsevier, Staebler laid out her evidence:
A UPenn professor now has six papers with a correction, expression of concern, or retraction in two PLOS journals after one published an extensive correction to a 2018 paper.
The correction adds to two retractions and three expressions of concern for papers in PLOS Pathogens and PLOS ONE with Erle Robertson, a microbiology professor and vice chair of research for the department of otorhinolaryngology at the University of Pennsylvania, as a senior author. The actions on each paper happened after commenters on PubPeer pointed out issues.
On a Saturday last November, Philip Tsichlis of The Ohio State University received an email no researcher wants to get.
Another scientist had tried to replicate a finding in a recent paper of his, and couldn’t. “We believe that our results should lead to some revision of the model you propose,” stated the email, which was released to us by OSU following a public records request.
It turned out that was an understatement. The email eventually led Tsichlis to discover data fabrication in that paper and a related article. Within a week, he requested the retraction of both papers, one in Communications Biology and the other in Nature Communications, both Springer Nature journals. One was retracted in December, but not the other.
In an email to a Nature Communications editor on November 22nd, Tsichlis wrote:
This has been a nightmare and I blame myself for not having detected it earlier. However, we cannot go back. I hope that we will retract this paper as soon as possible.
A journal has retracted a paper reporting the results of a clinical trial in which a drug cut COVID-19 hospitalization for men by 90%.
The research group’s other work has attracted a lot of attention in Brazil – including praise from president Jair Bolsonaro and criticism from research regulators – for their dramatic results. In a Twitter thread, one of the authors claimed, without evidence, that the journal “may have received bribery to persecute us and retract our study.”
A kidney research group led by a medical school dean has accumulated five retractions.
All five came within the last year, after commenters on PubPeer pointed out image similarities.
Joseph I. Shapiro, vice president and dean of the Joan C. Edwards School of Medicine of Marshall University in Huntington, West Virginia, is an author on each of the five papers and corresponding author for two. (Shapiro recently said he will be stepping down at the end of this month after ten years as dean, but will remain a tenured professor, according to a news report.)
A paper about the discovery of “the first potent and specific anti-COVID-19 drug” has been retracted after it emerged that the compound wasn’t so novel after all.
The article, published in May 2021 in Chemical Papers has been cited seven times, according to Clarivate Analytics’ Web of Science.
As the paper’s sole author, Amgad M. Rabie, writes in the abstract:
